Next generation sequencing and anti-cancer therapy
10.5124/jkma.2019.62.2.119
- Author:
Joohyuk SOHN
1
Author Information
1. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. oncosohn@yuhs.ac
- Publication Type:Original Article
- Keywords:
Next generation sequencing;
Cancer;
Targeted therapy;
Immunotherapy
- MeSH:
Biomarkers;
Consensus;
Drug Therapy;
Exome;
Humans;
Immunotherapy;
Mass Screening;
Off-Label Use;
Sequence Analysis, RNA
- From:Journal of the Korean Medical Association
2019;62(2):119-129
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Over the last two decades, the systemic treatment of cancer has evolved from cytotoxic chemotherapy to targeted therapy and now immunotherapy. Next-generation sequencing (NGS) is entering clinical applications for cancer treatment through the help of more powerful computational analyses. The increasing number of targeted therapies approved by regulatory authorities (RAs) with or without biomarkers necessitates the screening of multiple biomarkers using NGS, which is now approved and reimbursed by Korean RAs for some types of malignancies. However, the clinical utility of NGS remains to be established as a prerequisite for its routine incorporation into clinical practice. Currently, the best scenario of NGS use in clinics is to enroll patients into clinical trials based on the detection of biomarkers, but this is only possible in the hospitals conducting the specific trial. The other scenario is the off-label use of a targeted drug, but this requires social consensus for future implementation. The clinical applications of NGS are expanding in terms of its platforms, from targeted sequencing to whole exome and RNA sequencing, and in terms of systemic therapy, from targeted therapy to immunotherapy. Research into tumor mutational burden and neoantigens is shedding new light on the clinical use of NGS in immunotherapy.
